Michail Alevizakos1, Apostolos Gaitanidis2, Dimitrios Nasioudis3, Pavlos Msaouel4, Leonard J Appleman5. 1. Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA. Electronic address: mich.alevizakos@gmail.com. 2. Second Department of Surgery, University General Hospital of Alexandroupoli, Democritus University of Thrace Medical School, Alexandroupoli, Greece. 3. Department of Obstetrics and Gynecology, Hospital of the University of Pennsylvania, Philadelphia, PA. 4. Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. 5. Division of Hematology/Oncology, University of Pittsburgh, Pittsburgh, PA.
Abstract
BACKGROUND: Sarcomatoid renal cell carcinoma (sRCC) constitutes a rare and aggressive subtype of renal cell carcinoma. We aimed to investigate its clinicopathologic characteristics and outcomes at a national level. PATIENTS AND METHODS: We accessed the National Cancer Institute's Surveillance, Epidemiology, and End Results database (2010-2015) and extracted data on patients with sRCC. We estimated median, 1-, 3-, and 5-year disease-specific survival (DSS) probabilities after generation of Kaplan-Meier curves and used multivariable regression to evaluate variables associated with nephrectomy and DSS. RESULTS: A total of 879 patients with sRCC were identified; 60.9% patients had stage IV disease at diagnosis, and the median tumor size was 8.3 cm (interquartile range, 5.5-12 cm). The 5-year DSS were 77.7%, 67.8%, 35.4%, and 3.5% for patients with stage I, II, III, and IV disease at diagnosis, respectively; median DSS was 9 months (interquartile range, 4-42 months) for the entire cohort. Older age (hazard ratio [HR] = 1.01; 95% confidence interval [CI], 1.00-1.02), higher tumor stage (stage III vs. I: HR = 3.81; 95% CI, 2.18-6.67; stage IV vs. I: HR = 9.89; 95% CI, 5.80-16.98), and performance of nephrectomy (HR = 0.53; 95% CI, 0.43-0.66) were found to independently affect DSS. CONCLUSION: In the largest sRCC cohort to date, we found that most patients present with metastatic disease, and the prognosis for this disease remains extremely poor. Nephrectomy should be considered in all patients with acceptable surgical risk, including cytoreductive nephrectomy in carefully selected patients with metastatic disease.
BACKGROUND:Sarcomatoid renal cell carcinoma (sRCC) constitutes a rare and aggressive subtype of renal cell carcinoma. We aimed to investigate its clinicopathologic characteristics and outcomes at a national level. PATIENTS AND METHODS: We accessed the National Cancer Institute's Surveillance, Epidemiology, and End Results database (2010-2015) and extracted data on patients with sRCC. We estimated median, 1-, 3-, and 5-year disease-specific survival (DSS) probabilities after generation of Kaplan-Meier curves and used multivariable regression to evaluate variables associated with nephrectomy and DSS. RESULTS: A total of 879 patients with sRCC were identified; 60.9% patients had stage IV disease at diagnosis, and the median tumor size was 8.3 cm (interquartile range, 5.5-12 cm). The 5-year DSS were 77.7%, 67.8%, 35.4%, and 3.5% for patients with stage I, II, III, and IV disease at diagnosis, respectively; median DSS was 9 months (interquartile range, 4-42 months) for the entire cohort. Older age (hazard ratio [HR] = 1.01; 95% confidence interval [CI], 1.00-1.02), higher tumor stage (stage III vs. I: HR = 3.81; 95% CI, 2.18-6.67; stage IV vs. I: HR = 9.89; 95% CI, 5.80-16.98), and performance of nephrectomy (HR = 0.53; 95% CI, 0.43-0.66) were found to independently affect DSS. CONCLUSION: In the largest sRCC cohort to date, we found that most patients present with metastatic disease, and the prognosis for this disease remains extremely poor. Nephrectomy should be considered in all patients with acceptable surgical risk, including cytoreductive nephrectomy in carefully selected patients with metastatic disease.
Authors: Eliezer M Van Allen; Toni K Choueiri; Ziad Bakouny; David A Braun; Sachet A Shukla; Wenting Pan; Xin Gao; Yue Hou; Abdallah Flaifel; Stephen Tang; Alice Bosma-Moody; Meng Xiao He; Natalie Vokes; Jackson Nyman; Wanling Xie; Amin H Nassar; Sarah Abou Alaiwi; Ronan Flippot; Gabrielle Bouchard; John A Steinharter; Pier Vitale Nuzzo; Miriam Ficial; Miriam Sant'Angelo; Juliet Forman; Jacob E Berchuck; Shaan Dudani; Kevin Bi; Jihye Park; Sabrina Camp; Maura Sticco-Ivins; Laure Hirsch; Sylvan C Baca; Megan Wind-Rotolo; Petra Ross-Macdonald; Maxine Sun; Gwo-Shu Mary Lee; Steven L Chang; Xiao X Wei; Bradley A McGregor; Lauren C Harshman; Giannicola Genovese; Leigh Ellis; Mark Pomerantz; Michelle S Hirsch; Matthew L Freedman; Michael B Atkins; Catherine J Wu; Thai H Ho; W Marston Linehan; David F McDermott; Daniel Y C Heng; Srinivas R Viswanathan; Sabina Signoretti Journal: Nat Commun Date: 2021-02-05 Impact factor: 14.919
Authors: Jose A Karam; A Ari Hakimi; Kyle A Blum; Sounak Gupta; Satish K Tickoo; Timothy A Chan; Paul Russo; Robert J Motzer Journal: Nat Rev Urol Date: 2020-10-13 Impact factor: 14.432